NATCO PHARMA
Back to Balance Sheet
|
NATCO PHARMA Last 5 Year Deferred Tax Assets / Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Deferred Tax Assets / Liabilities | ₹-19 Cr | ₹12 Cr | ₹30 Cr | ₹41 Cr | ₹26 Cr |
What is the latest Deferred Tax Assets / Liabilities ratio of NATCO PHARMA ?
Year | Deferred Tax Assets / Liabilities |
---|---|
Mar2024 | ₹-19 Cr |
Mar2023 | ₹12 Cr |
Mar2022 | ₹30 Cr |
Mar2021 | ₹41 Cr |
Mar2020 | ₹26 Cr |
How is Deferred Tax Assets / Liabilities of NATCO PHARMA Trending?
Years | Deferred Tax Assets / Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹-19 Cr | Negative | |
Mar2023 | ₹12 Cr | -58.80 | |
Mar2022 | ₹30 Cr | -27.12 | |
Mar2021 | ₹41 Cr | 59.46 | |
Mar2020 | ₹26 Cr | - |
Compare Deferred Tax Assets / Liabilities of peers of NATCO PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
NATCO PHARMA | ₹22,197.7 Cr | 2.2% | -14.3% | 47.1% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹428,557.0 Cr | 2.3% | -0.8% | 32.7% | Stock Analytics | |
DIVIS LABORATORIES | ₹156,994.0 Cr | 3.2% | 1.1% | 51.5% | Stock Analytics | |
CIPLA | ₹116,494.0 Cr | 0.3% | -2% | 10% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹109,297.0 Cr | -1.8% | 2.7% | 12.7% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹100,035.0 Cr | 2% | 1.5% | 38% | Stock Analytics |
NATCO PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NATCO PHARMA | 2.2% |
-14.3% |
47.1% |
SENSEX | -1% |
-5% |
5.6% |
You may also like the below Video Courses